Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keli An

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Drug Discovery Today|January 27, 2018
Recent advances in siRNA delivery for cancer therapy using smart nanocarriersPenghui Zhang, Keli An, Xiaoman Duan, et al.
ACS Applied Materials & Interfaces|August 8, 2023
Thermo-Chemical Resistance to Combination Therapy of Glioma Depends on Cellular Energy LevelJinbin Qiu, Zhijie Li, Keli An, et al.
Journal of the American Chemical Society|December 11, 2025
pH-Isomerizable Acylhydrazone-Based Ionizable Lipids for Spleen-Targeted mRNA VaccinesXuqian Deng, Yan Li, Xiaolan Zhu, et al.
Nature Communications|April 29, 2023
Hydrogel dressing integrating FAK inhibition and ROS scavenging for mechano-chemical treatment of atopic dermatitisYuanbo Jia, Jiahui Hu, Keli An, et al.
Journal of the American Chemical Society|July 2, 2024
Stimuli-Responsive mRNA Vaccines to Induce Robust CD8<sup>+</sup> T Cell Response via ROS-Mediated Innate Immunity BoostingLinying Dong, Xuqian Deng, Yan Li, et al.
Neoplasia (New York, N.Y.)|June 16, 2026
Hypoxia-activated PROTAC for dual inhibition of FAK and EGFR enables synergistic mechano-chemical cancer therapyKeli An, Yuan Li, Chunyu Cao, et al.
Angewandte Chemie (International Ed. in English)|October 15, 2024
Programmable Circular Multivalent Nanobody-Targeting Chimeras (mNbTACs) for Multireceptor-Mediated Protein Degradation and Targeted Drug DeliveryShiqi Jiang, Xinru Lv, Zhenlin Ouyang, et al.
Journal of the American Chemical Society|December 4, 2024
Programmable Circular Multispecific Aptamer-Drug Engager to Broadly Boost Antitumor ImmunityJinling Chen, Hongli Chi, Chao Wang, et al.
Angewandte Chemie (International Ed. in English)|July 20, 2023
Stimuli-Responsive PROTACs for Controlled Protein DegradationKeli An, Xuqian Deng, Hongli Chi, et al.
Journal of the American Chemical Society|April 13, 2026
Dual-Targeting Multivalent Aptamer-Drug Hybrids for Synergistic Cancer ImmunotherapyHongli Chi, Yanlin Du, Wei Lv, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Drug Discovery Today|January 27, 2018
Recent advances in siRNA delivery for cancer therapy using smart nanocarriersPenghui Zhang, Keli An, Xiaoman Duan, et al.
ACS Applied Materials & Interfaces|August 8, 2023
Thermo-Chemical Resistance to Combination Therapy of Glioma Depends on Cellular Energy LevelJinbin Qiu, Zhijie Li, Keli An, et al.
Journal of the American Chemical Society|December 11, 2025
pH-Isomerizable Acylhydrazone-Based Ionizable Lipids for Spleen-Targeted mRNA VaccinesXuqian Deng, Yan Li, Xiaolan Zhu, et al.
Nature Communications|April 29, 2023
Hydrogel dressing integrating FAK inhibition and ROS scavenging for mechano-chemical treatment of atopic dermatitisYuanbo Jia, Jiahui Hu, Keli An, et al.
Journal of the American Chemical Society|July 2, 2024
Stimuli-Responsive mRNA Vaccines to Induce Robust CD8<sup>+</sup> T Cell Response via ROS-Mediated Innate Immunity BoostingLinying Dong, Xuqian Deng, Yan Li, et al.
Neoplasia (New York, N.Y.)|June 16, 2026
Hypoxia-activated PROTAC for dual inhibition of FAK and EGFR enables synergistic mechano-chemical cancer therapyKeli An, Yuan Li, Chunyu Cao, et al.
Angewandte Chemie (International Ed. in English)|October 15, 2024
Programmable Circular Multivalent Nanobody-Targeting Chimeras (mNbTACs) for Multireceptor-Mediated Protein Degradation and Targeted Drug DeliveryShiqi Jiang, Xinru Lv, Zhenlin Ouyang, et al.
Journal of the American Chemical Society|December 4, 2024
Programmable Circular Multispecific Aptamer-Drug Engager to Broadly Boost Antitumor ImmunityJinling Chen, Hongli Chi, Chao Wang, et al.
Angewandte Chemie (International Ed. in English)|July 20, 2023
Stimuli-Responsive PROTACs for Controlled Protein DegradationKeli An, Xuqian Deng, Hongli Chi, et al.
Journal of the American Chemical Society|April 13, 2026
Dual-Targeting Multivalent Aptamer-Drug Hybrids for Synergistic Cancer ImmunotherapyHongli Chi, Yanlin Du, Wei Lv, et al.
Pageof 2